Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page
- Check4 days agoChange DetectedAdded a Locations section listing Florida. Updated the page revision to v3.3.3; the Florida Locations label and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedMinor edits to the Publications section note clarifying that publications are provided voluntarily by the person entering information about the study and pertain to the results. A new Revision: v3.3.1 was added; the previous version was v3.2.0.SummaryDifference0.1%

- Check40 days agoChange DetectedNotice about government funding and NIH Clinical Center operating status was removed from the page. All study details and trial information remain unchanged.SummaryDifference0.4%

- Check54 days agoChange DetectedAdded a Study Results section and a Publications entry (Biomarker Research 2022) for pembrolizumab activity in Fanconi anemia pathway tumors on the Study Details page.SummaryDifference0.5%

- Check83 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference4%

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.